Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lucentra
- Development stage
- Phase 4
- Lead developer
- Espad Pharmed
- Administration
- Intracutaneous, Subcutaneous, Dermal
01
Overview
Lucentra is a hyaluronic acid-based dermal filler developed and manufactured by Espad Pharmed. It is designed for aesthetic and cosmetic applications, including soft-tissue augmentation, facial volumization, and the correction of facial wrinkles and folds. Administered via dermal, subcutaneous, or intracutaneous injection, Lucentra utilizes cross-linked hyaluronic acid to provide immediate structural support and volume by physically occupying space and attracting water molecules within the skin's extracellular matrix. It is primarily used in the field of aesthetic medicine to enhance facial contours and reduce the appearance of aging.
- Brand names
- Lucentra
Beyond the preview
Go deeper on Lucentra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lucentra.